Nov 30, 2022
Press Release - PhageTech, Inc. (PhageTech), a privately held company pioneering a novel point-of-care diagnostic system, today announced the completion of enrollment in its trial of the CarePoint Electrochemical ELISA (CarePoint-ELISA) and Virus BioResistor (VBR) for bladder cancer screening. The trial was conducted at three Orange County, CA area hospitals and Vanderbilt University Medical Center in Nashville, TN, all specializing in bladder cancer treatment.
PhageTech, Inc. (PhageTech), was announced as winner of the 2022 UCI Chao Family Comprehensive Cancer Center “Pitch Day Award”. The award is granted annually to support promising new companies developing novel treatment and diagnostic solutions to cancer.
Press Release - PhageTech Clinical Trial Start
UCI Beall Applied Innovation Screens UCI Life Science Startups Focused on COVID-19 Countermeasures
UC Irvine chemistry professors develop method for early cancer detection
May 29, 2017
Oct. 01, 2015
EvoNexus company PhageTech closes $2.4 million Series A financing for commercialization of one- minute blood and urine test.